title: Clinical efficacy of highly purified, doubly virus-inactivated factor VIII/von Willebrand factor concentrate (Fanhdi) in the treatment of von Willebrand disease: a retrospective clinical study.
abstract: The goal of therapy in patients with von Willebrand disease (vWD) is to correct the dual defect of primary haemostasis and intrinsic coagulation reflected by low levels of von Willebrand factor (vWF) and factor VIII coagulant activity (FVIII:C). Factor VIII/von Willebrand factor (FVIII/vWF) concentrates are currently the treatment of choice in vWD patients unresponsive to desmopressin (DDAVP). However, only few studies on their clinical use are available so far. The main objective of this study was to retrospectively evaluate the clinical efficacy of a highly purified, doubly virus-inactivated FVIII/vWF concentrate with a high content of FVIII/vWF (Fanhdi). Twenty-two patients with congenital vWD have been treated from 1999 to 2001 at eight specialized centres belonging to the Italian Association of Hemophilia Centers (AICE). Ten males and 12 females, median age 28.5 years, range 5-70 years) had type 3 vWD (six cases), DDAVP-unresponsive type 1 (nine cases) and type 2B (seven cases). The study drug was given to stop or prevent 12 bleeding episodes or to prevent excessive bleeding during 14 surgical or invasive procedures. Overall, replacement therapy with the concentrate showed an excellent to good clinical efficacy in 92% of bleeding episodes and in 93% of surgical procedures. No adverse events occurred during 1,601 infusions, accounting for a total of 304,500 IU of FVIII:C administered. These results confirm the efficacy and safety of this concentrate in the management of bleeding episodes and in the prevention of excessive bleeding during major and minor surgery.
authors.affiliation: Department of Internal Medicine, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, IRCCS Ospedale Maggiore, University of Milan, Italy. augusto.federici@unimi.it
authors.forename: A B
authors.initials: AB
authors.lastname: Federici
authors.forename: F
authors.initials: F
authors.lastname: Baudo
authors.forename: C
authors.initials: C
authors.lastname: Caracciolo
authors.forename: G
authors.initials: G
authors.lastname: Mancuso
authors.forename: M G
authors.initials: MG
authors.lastname: Mazzucconi
authors.forename: R
authors.initials: R
authors.lastname: Musso
authors.forename: P C
authors.initials: PC
authors.lastname: Schinco
authors.forename: R
authors.initials: R
authors.lastname: Targhetta
authors.forename: P
authors.initials: P
authors.lastname: Mannuccio Mannucci
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D002675:Child, Preschool; D004338:Drug Combinations; D005169:Factor VIII / Q000627:therapeutic use*; D005260:Female; D006470:Hemorrhage / Q000188:drug therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D019990:Perioperative Care / Q000379:methods; D019106:Postoperative Hemorrhage / Q000517:prevention & control; D012189:Retrospective Studies; D016896:Treatment Outcome; D038301:Virus Inactivation; D014842:von Willebrand Diseases / Q000150:complications / Q000188:drug therapy*; D014841:von Willebrand Factor / Q000627:therapeutic use*
chemical_list: D004338:Drug Combinations; D014841:von Willebrand Factor; D005169:Factor VIII